Issue 10/2022
Content (7 Articles)
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Anastasia Geladaris, Sebastian Torke, Martin S. Weber
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
Niloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, Yena Lee, Joshua D. Rosenblat, Kayla M. Teopiz, Leanna M. W. Lui, Mehala Subramaniapillai, Kangguang Lin, Flora Nasri, Nelson Rodrigues, Hartej Gill, Orly Lipsitz, Bing Cao, Roger Ho, David Castle, Roger S. McIntyre
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research
Joseph Junior Damba, Katie Bodenstein, Paola Lavin, Jessica Drury, Harmehr Sekhon, Christel Renoux, Emilie Trinh, Soham Rej, Kyle T. Greenway
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
Adam Strzelczyk, Susanne Schubert-Bast
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study
Yaroslav Winter, Katharina Sandner, Thomas Ludger Vieth, Nico Melzer, Sven Klimpe, Sven G. Meuth, Sergiu Groppa
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab
Michael Auer, Angelika Bauer, Antonia Oftring, Dagmar Rudzki, Harald Hegen, Gabriel Bsteh, Franziska Di Pauli, Klaus Berek, Anne Zinganell, Thomas Berger, Markus Reindl, Florian Deisenhammer
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Tina Nie, Hannah A. Blair